Superworth

Cingulate EPS CING

Diluted earnings per share by quarter and over the last twelve months, from 2022.

Last 12 months, to Jun 30, 2026
−$3.68
Latest quarter, Q2 FY26
−$0.45
Fiscal year 2025
−$4.48

Cingulate's earnings per share was −$3.68 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.45.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$4.48n/a
FY2024−$16.92n/a
FY2023−$220.90n/a
FY2022n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.45n/a−$3.68
Q1 FY26−$0.95n/a−$4.37
Q4 FY25−$0.93n/a−$4.48
Q3 FY25−$1.35n/a−$5.45
Q2 FY25−$1.14n/a−$6.44
Q1 FY25−$1.06n/a−$10.77
Q4 FY24−$1.90n/a−$16.92
Q3 FY24−$2.34n/a−$71.57
Q2 FY24−$5.47n/a−$141.83
Q1 FY24−$7.21n/a−$143.15
Q4 FY23−$56.55n/a−$220.90
Q3 FY23−$72.60n/a−$256.15

Against its peers

Companies in Drug Manufacturers - General nearest Cingulate's size, closest first, today.

CompanyEPS, 12 monthsGrowth
CINGCingulate−$3.68
LFVNLifevantage$0.40−46% a year
SPROSpero Therapeutics$0.11
ATNMActinium Pharmaceuticals$0.36
NATRNatures Sunshine Products$1.01+36% a year
ARVNArvinas$0.16
PBYIPuma Biotechnology$0.52−47% a year
IRWDIronwood Pharmaceuticals$0.77
ZVRAZevra Therapeutics$0.93
CRMDCorMedix$2.13+184% a year
Peer median$0.52

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Cingulate

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.